Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 6/20 | 0.53 |
| ▸ | RBP4 | P02753 | 6/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2513644 | 1.00 | MTNR1A (0.56) | MTNR1AHTR2CRBP4CHRNB2CHRNA4 | |
| SCHEMBL13525298 | 1.00 | MTNR1A (0.56) | MTNR1AHTR2CRBP4CHRNB2CHRNA4 | |
| SCHEMBL1269156 | 0.78 | MTNR1A (0.61) | MTNR1A | |
| SCHEMBL10759562 | 0.75 | MTNR1A (0.61) | MTNR1ATP53MAPT | |
| SCHEMBL31147241 | 0.75 | TP53 (0.56) | HTR2CRBP4CHRNB2CHRNA4TP53 | |
| SCHEMBL23778971 | 0.75 | MTNR1A (0.61) | MTNR1ACHRNB2CHRNA4 | |
| SCHEMBL7569154 | 0.75 | TP53 (0.56) | HTR2CRBP4CHRNB2CHRNA4TP53 | |
| SCHEMBL194726 | 0.73 | HTR2C (0.51) | HTR2CRBP4TP53HTR2BMAPT | |
| SCHEMBL35210378 | 0.73 | MTNR1A (0.55) | MTNR1ATP53MAPT | |
| SCHEMBL5007618 | 0.73 | HTR2C (0.75) | HTR2CRBP4CHRNB2CHRNA4HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245223-A1 | HETEROCYCLIC COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2011-10-06 | — | — | US | claimed |
| EP-1889842-A1 | HETEROCYCLIC COMPOUND | Japan Tobacco, Inc. (JP) | 2008-02-20 | — | — | EP | claimed |
| US-20070072908-A1 | Heterocyclic compounds | JAPAN TOBACCO INC. (JP) | 2007-03-29 | — | — | US | claimed |
| US-20110245223-A1 | HETEROCYCLIC COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-2103603-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | Japan Tobacco Inc. (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-1889842-A1 | HETEROCYCLIC COMPOUND | Japan Tobacco, Inc. (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20070072908-A1 | Heterocyclic compounds | JAPAN TOBACCO INC. (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245223-A1 | HETEROCYCLIC COMPOUNDS | HSD11B1, HSD11B2, CYP11B1 | MTNR1A 419/4885HTR2C 1450/4885RBP4 2438/4885 |
| US-20070072908-A1 | Heterocyclic compounds | HSD11B1, HSD11B2, CYP11B1 | MTNR1A 419/4885HTR2C 1450/4885RBP4 2438/4885 |
| US-20100010219-A1 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | HSD11B1, HSD11B2, HSD17B11 | MTNR1A 1774/4885HTR2C 3041/4885RBP4 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.